Table 2.

Table 2 Randomized controlled trials of prevention of MCI progressing to dementia or AD

Author	Treatment	N (duration)	Outcomes	Results	Comments
Feldman et al (73)	Rivastigmine	1018 (48 months)	1. Progression to AD 2. Change on composite cognitive score	No difference between drug and placebo	No difference in MRI measure (ventricular volume)
Salloway et al (74)	Donepezil	270 (6 months)	1. Global impression of change
			2. Change in delayed logical recall	No difference between drug and placebo
Petersen et al (75)	Donepezil ± Vitamin E	769 (36 months)	Incident AD	1. Donepezil was not protective on primary outcome, but had a limited effect at 12 months in a secondary analysis.	1. Donepezil effect observed at 36 months in ApoE4 carriers
				2. No effect of Vitamin E	2. No effect on rate of brain atrophy (76)
MCI - mild cognitive impairment; AD - Alzheimer's disease; MRI - magnetic resonance imaging
Two trials of galantamine in MCI have been reported as negative in a recent systematic review (72)